Related references
Note: Only part of the references are listed.ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2013)
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
Andre Goy et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2012)
Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma
Laia Rosich et al.
CLINICAL CANCER RESEARCH (2012)
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy
Monica Civallero et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Christoph Renner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
Areumnuri Kim et al.
LEUKEMIA RESEARCH (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
Sara Galimberti
Cancer Management and Research (2012)
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Patricia Perez-Galan et al.
BLOOD (2011)
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
Stephen M. Ansell et al.
LANCET ONCOLOGY (2011)
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
T. E. Witzig et al.
LEUKEMIA (2011)
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
B. Weigelt et al.
ONCOGENE (2011)
Is There a Role for Watch and Wait in Patients With Mantle Cell Lymphoma?
Peter Martin et al.
SEMINARS IN HEMATOLOGY (2011)
Targeting the PI3K/AKT/mTOR Pathway in Non-Hodgkin's Lymphoma: Results, Biology, and Development Strategies
Jonathan H. Schatz
CURRENT ONCOLOGY REPORTS (2011)
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial
Owen A. O'Connor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
Jessica Dal Col et al.
BLOOD (2008)
Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis
Tiemo Katzenberger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group
Stephen M. Ansell et al.
CANCER (2008)
The international harmonization project for response criteria in lymphoma clinical trials
Bruce D. Cheson
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2007)
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma
T. Haritunians et al.
LEUKEMIA (2007)
Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma
Evangelia Peponi et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma
Martina Rudelius et al.
BLOOD (2006)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFβ signalling pathways
EG Rizzatti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
The TOR pathway: A target for cancer therapy
MA Bjornsti et al.
NATURE REVIEWS CANCER (2004)
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
JE Romaguera et al.
CANCER (2003)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald et al.
CANCER CELL (2003)
Share Paper
